Evidence map›Paper›PMID 33021720›Full record

ArticleMolecular biology reports2020

Investigation of 8-methoxy-3-(4-nitrobenzoyl)-6-propyl-2H-chromen-2-one as a promising coumarin compound for the development of a new and orally effective antileishmanial agent.

Eduardo de Figueiredo Peloso, Rafaella Junqueira Merli, Patrícia Ferreira Espuri, Juliana Barbosa Nunes, Fábio Antônio Colombo, Elkin José Torres Sierra, Daniela Carvalho de Paulo, Marcelo Henrique Dos Santos, Diogo Teixeira Carvalho, Marcos José Marques

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 24 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Eduardo de Figueiredo PelosoDepartment of Biochemistry, Institute of Biomedical Sciences, Universidade Federal de Alfenas, 700 Gabriel Monteiro da Silva St, Alfenas, MG, CEP 37130-001, Brazil. eduardofpeloso@yahoo.com.br.
Rafaella Junqueira MerliDepartment of Biochemistry, Institute of Biomedical Sciences, Universidade Federal de Alfenas, 700 Gabriel Monteiro da Silva St, Alfenas, MG, CEP 37130-001, Brazil.
Patrícia Ferreira EspuriLaboratory of Parasitology, Department of Pathology and Parasitology, Institute of Biomedical Sciences, Universidade Federal de Alfenas, 700 Gabriel Monteiro da Silva St, Alfenas, MG, CEP 37130-001, Brazil.
Juliana Barbosa NunesLaboratory of Pathology of Infectious Diseases, Department of Pathology, Medical School, São Paulo University, Sao Paulo, SP, CEP 01246-903, Brazil.
Fábio Antônio ColomboLaboratory of Clinical Parasitology, Department of Clinical and Toxicological Analysis, Faculty of Pharmaceutical Sciences, Universidade Federal de Alfenas, Alfenas, MG, Brazil.
Elkin José Torres SierraLaboratory of Research in Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Universidade Federal de Alfenas, Alfenas, MG, Brazil.
Daniela Carvalho de PauloLaboratory of Research in Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Universidade Federal de Alfenas, Alfenas, MG, Brazil.
Marcelo Henrique Dos SantosDepartment of Chemistry, Universidade Federal de Viçosa, Vicosa, MG, CEP 36570-900, Brazil.
Diogo Teixeira CarvalhoLaboratory of Research in Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Universidade Federal de Alfenas, Alfenas, MG, Brazil.
Marcos José MarquesLaboratory of Parasitology, Department of Pathology and Parasitology, Institute of Biomedical Sciences, Universidade Federal de Alfenas, 700 Gabriel Monteiro da Silva St, Alfenas, MG, CEP 37130-001, Brazil. marques.prppg@gmail.com.ORCID http://orcid.org/0000-0003-3459-3169
Universidade Federal de Alfenas · BRUniversidade de São Paulo · BRUniversidade Federal de Viçosa · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico INCT-INOFARFundação de Amparo à Pesquisa do Estado de Minas Gerais (BR) PPM-00482-16
6 · The paper itself

Abstract

Changes in host immunity and parasite resistance to drugs are among the factors that contribute to decreased efficacy of antiparasitic drugs such as the antimonial compounds pentamidine, amphotericin (AMP B) and miltefosine. Bioactive natural products could be alternatives for the development of new drugs to treat neglected human diseases such as leishmaniasis. Natural coumarins and synthetic analogues have shown leishmanicidal activity, mainly in vitro. This study investigated the in vitro and in vivo leishmanicidal activity of synthetic coumarin compounds (C1-C5) in parasites Leishmania (L.) amazonensis and L. (L.) infantum chagasi. The cytotoxicity of these compounds in mammalian cells and their influence on production of reactive oxygen species was also investigated. In vitro assays showed that 8-methoxy-3-(4-nitrobenzoyl)-6-propyl-2H-chromen-2-one (C4) was as active as AMP B mainly in the amastigote form (p < 0.05); C4 presented a selectivity index (65.43) four times higher than C2 (15.4) in L. amazonensis and six times higher (33.94) than C1 (5.46) in L. infantum chagasi. Additionally, coumarin C4 reduced the H

Indexed as

Administration, OralAmphotericin BAnimalsAntiprotozoal AgentsCoumarinsCricetinaeFemaleHost-Parasite InteractionsHydrogen PeroxideLeishmaniaLeishmaniasisMembrane Potential, MitochondrialMesocricetusMolecular StructureSpecies SpecificityAmphotericin BAntiprotozoal AgentsCoumarinsHydrogen PeroxideCoumarinsHydrogen peroxide productionLeishmanicidal activityNitro compoundsOral route

Identifiers

PMID33021720
OpenAlexW3089814703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.